[Clinical applications of the carcinoembryonic antigen (CEA) determination in colorectal cancer (observations of 119 cases)].
The AA., on the base of their personal experience and the data of literature, value clinical uses of dosage of carcino-embryonic antigen (CEA), made on the blood of patients who suffered of colon-rectal cancer. Their personal experience is based on 119 patients, 70 who had radical exeresis of neoplasm and 49 the palliative treatment. In the patients who had radical treatment the evolution of disease was overseen with this method for a period from a minimum of 1 year to 3 years and in 10 cases they could put in evidence the restarting of neoplasm too early. In regard to the patients who had a palliative treatment, with the observations of CEA works, they obtained a quantitative valuation of antiblastic chemiotherapy effects and electrocoagulative treatment. The AA. end that, while CEA dosage has not negligible limits for a diagnosis, this method is very useful for the precocious diagnosis of neoplasm restarting. On the contrary the information, that we can obtain about the effects of palliative therapy, is limited.
D000328:Adult; D000368:Aged; D002272:Carcinoembryonic Antigen / Q000032:analysis*; D003110:Colonic Neoplasms / Q000276:immunology* / Q000601:surgery; D005188:False Negative Reactions; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010166:Palliative Care; D011184:Postoperative Period; D011379:Prognosis; D012004:Rectal Neoplasms / Q000276:immunology* / Q000601:surgery
D002272:Carcinoembryonic Antigen
Applicazioni cliniche del dosaggio dell'antigene carcioembrionario (CEA) nel cancro del colon-retto. (osservazioni su 119 casi).